Revenue → Gross profit: $64BPharmaceutical → Revenue: $53BRevenue → Cost of revenue: $31BMedical devices → Revenue: $27BGross profit → SG&A: $25BGross profit → Operating profit: $23BOperating profit → Net profit: $18BImmunology → Pharmaceutical: $17BOncology → Pharmaceutical: $16BConsumer health → Revenue: $15BGross profit → R&D: $15BSurgery → Medical devices: $10BOrthopaedics → Medical devices: $9BNeuroscience → Pharmaceutical: $7BInfectious diseases → Pharmaceutical: $5BVision → Medical devices: $5BInterventional → Medical devices: $4BOther pharma → Pharmaceutical: $4BOperating profit → Tax: $4BPulmonary → Pharmaceutical: $3BOperating profit → Other: $2BGross profit → In-process R&D: $1BGross profit → Restructuring: $0BInterest income → Net profit: $0BConsumer health: $15BRevenue: $95BImmunology: $17BPharmaceutical: $53BInfectious diseases: $5BNeuroscience: $7BOncology: $16BPulmonary: $3BOther pharma: $4BMedical devices: $27BInterventional: $4BOrthopaedics: $9BSurgery: $10BVision: $5BGross profit: $64BCost of revenue: $31BOperating profit: $23BSG&A: $25BR&D: $15BIn-process R&D: $1BRestructuring: $0BInterest income: $0BNet profit: $18BOther: $2BTax: $4Bcreated with SankeyArt.comConsumer health$15B-1% Y/YRevenue$95B1% Y/YImmunology$17BPharmaceutical$53B2% Y/YInfectious diseases$5BNeuroscience$7BOncology$16BPulmonary$3BOther pharma$4BMedical devices$27B1% Y/YInterventional$4BOrthopaedics$9BSurgery$10BVision$5BGross profit$64BFlat Y/YCost of revenue$31B4% Y/YOperating profit$23B1% Y/YSG&A$25B-5% Y/YR&D$15B-5% Y/YIn-process R&D$1B-13% Y/YRestructuring$321MInterest income$214MNet profit$18B-14% Y/YOther$2B283% Y/YTax$4B99% Y/YJohnson & Johnson FY22 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3